Implementing SC Swansea

Implementing OCREVUS SC at Morriston Hospital, Swansea

In September 2024, Morriston Hospital led the way becoming the first hospital in the UK to administer OCREVUS SC to a patient. These videos offer the multidisciplinary team (MDT) perspective on the implementation process and the impact of introducing Ocrevus SC for people with MS.

You will also hear the team highlight improvements in their service capacity and efficiency in the clinic compared to the IV formulation.

Charles-Henry Her, Neurology Pharmacist

Hear about the implementation of OCREVUS SC and how the pharmacy team managed the process from formulary approval to creating a dedicated storage system, resulting in a seamless transition from OCREVUS IV.

7 min watch

Dr. Gillian Ingram and Dr. Owen Pearson, Consultant Neurologists

They discuss their motivations for the switch, including the opportunity to free up infusion capacity and offer patients a faster treatment vs OCREVUS IV.

6 min watch

Alexandra Strong, Lead Clinical Nurse Specialist Jill Rowe Neurology Ambulatory Care

Alexandra shares her experience implementing OCREVUS SC in Swansea. Offering practical tips for overcoming barriers within the infusion unit and highlights the impact OCREVUS SC is having on unit capacity.

8 min watch

Helen Owen, Lead MS Nurse Specialist

Helen shares her perspective on the patient experience with OCREVUS SC. From her work at Morriston Hospital, Swansea, she discusses the key ways this treatment impacts patients.

5 min watch

If you would like support with training, reach out to a member of our team.

References:

OCREVUS IV Summary of Product Characteristics
2. OCREVUS SC Summary of Product Characteristics

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

References:

Adverse reactions should be reported by brand name and batch number.